Thank you for your interest in our study titled: "Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo-Controlled Trial" 

Your responses to this survey will determine whether you are eligible to participate in this study.

First, there are a few things about this study that you may like to know before you decide to participate:

  • This study plans to learn more about cannabidiol (CBD) for individuals with mild cognitive impairment and the effects of CBD on health-related markers of Alzheimer's Disease. 
  • You are being asked to be in this research study because you have expressed a desire to use CBD for mild cognitive impairment.
  • If you join the study, you will be randomized to receive one of three study medications that you will take for a period of 24 weeks: 200 mg/day of CBD that includes trace amounts of THC (< 0.3%), 200 mg/day of CBD that includes no THC, or 200 mg/day of Hemp Seed Oil, which does not contain any CBD or THC.
    • You will not know which medication group you are in.
  • There will be six in-person visits during the 24-week clinical trial, which will take place on the University of Colorado Anschutz Medical Campus ("AMC") in Aurora, Colorado. (Address: 1890 N Revere Ct, Aurora, CO 80045).
  • These visits may include a blood draw, a urine drug test, a pregnancy test, completion of cognitive tasks, surveys, and questionnaires, depending on the study week.
  • Total study participation will last 26 weeks.
  • A researcher coordinator will contact you over the phone to do a quick "check-in" regarding your health and tolerance to the medication. This will occur twice in between your in-person visits. Therefore, you will speak to a researcher over the phone 8 times during the 24-week clinical trial.
  • Total compensation for the study can be up to $250.

Before you come in to learn more about the study, it would be helpful to see if you are likely to qualify to be in the study.  In order to do this, we would like to ask you some eligibility questions, which will include questions about your medical and psychiatric history, substance use, and medications you are taking. It should take about 15 minutes to go through these questions. 

Some of the questions may make you uncomfortable; you do not have to answer any question that you would not like to answer, but without answers to these questions, you will not be eligible to participate in the study.  We will not record your name or any other information that would identify you on the form we use to record your answers until we know you have qualified for the study; at that time, we will keep this information secure.  If you do not enroll in this study, we will keep the information we collect during this pre-screening but there will be no way for anyone to link that information to you. 

If you have any questions for the study coordinator about this survey, you can call them at 303-724-2210.

We are also required to give you the number of COMIRB, the Ethics Board that oversees our research: it is (303) 724-1055, in case you have any questions or concerns for them.

COMIRB# 23-0619

Version Date: 11.17.2023

Loading... Loading...
You have selected an option that triggers this survey to end right now.
To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.